Malignant hyperthermia (MH) manifests as a life-threatening pharmacogenetic disorder triggered by depolarizing neuromuscular blockers (e.g., succinylcholine) or halogenated inhalational anesthetics (e.g., sevoflurane), characterized by uncontrolled skeletal muscle calcium release due to ryanodine receptor type 1 (RYR1) gene mutations, culminating in catastrophic hypermetabolism with characteristic triad: hypercapnia (EtCO2>55 mmHg), metabolic acidosis (pH<7.2), and hyperthermia (core temperature >40°C). The gene discussed is RYR1; the disease is Malignant hyperthermia.